(Total Views: 620)
Posted On: 06/29/2020 1:53:02 PM
Post# of 154779
I just read an interesting post on the Yahoo board that I am, frankly, surprised I had not really considered.
We've all been expressing angst and concern regarding the low power of the 50 subject interim look at the P3 S/C trial.
With CytoDyn having a really good idea of those results no later than yesterday (and probably last week, if not earlier), why would CytoDyn ever agree to a 25 subject Mexico trial having the exact same protocol and a much lower intrinsic power (25 vs 50), if they didn't think it would generate results that could lead to approval?
We've all been expressing angst and concern regarding the low power of the 50 subject interim look at the P3 S/C trial.
With CytoDyn having a really good idea of those results no later than yesterday (and probably last week, if not earlier), why would CytoDyn ever agree to a 25 subject Mexico trial having the exact same protocol and a much lower intrinsic power (25 vs 50), if they didn't think it would generate results that could lead to approval?
(4)
(0)
